Last updated: August 1, 2026
Phenindione has no meaningful current clinical-development program, no established FDA commercial market, and no credible pathway to renewed mainstream use. The oral vitamin K antagonist was largely displaced by warfarin because of serious immune-mediated and hematologic toxicity. Current commercial demand is limited to historical-use markets, archival supply, or tightly controlled legacy prescribing. The 2025-2030 market outlook is effectively negligible.
What is phenindione and how does it work?
Phenindione is an oral anticoagulant in the indandione class. It reduces hepatic synthesis of vitamin K-dependent coagulation factors, including factors II, VII, IX and X, producing an anticoagulant effect similar to warfarin.
Phenindione was developed before direct oral anticoagulants and was used historically for indications such as:
- Venous thromboembolism prevention and treatment
- Atrial fibrillation-related embolic risk
- Postoperative thromboprophylaxis
- Mechanical-heart-valve anticoagulation
Its clinical use declined because the drug has a narrow therapeutic index and a comparatively unfavorable adverse-event profile. Reported reactions included hypersensitivity, fever, rash, hepatitis, agranulocytosis, thrombocytopenia, nephrotic syndrome and other immune-mediated complications. These risks made continued treatment less attractive when warfarin and later direct oral anticoagulants became available.
Phenindione is not a direct factor Xa inhibitor or direct thrombin inhibitor. It requires coagulation monitoring and dose adjustment, although modern standardized international normalized ratio, or INR, monitoring was developed primarily around warfarin therapy.
What is the current clinical-trial status of phenindione?
Phenindione has no active clinical development program of commercial significance. Public clinical-trial registries do not identify a contemporary Phase 1, Phase 2 or Phase 3 program supporting a new indication, formulation or regulatory filing for phenindione [1].
Clinical-trial pipeline
| Development category |
Current status |
| Phase 1 trials |
No active commercial program identified |
| Phase 2 trials |
No active program identified |
| Phase 3 trials |
No active program identified |
| Regulatory-enabling studies |
No current program identified |
| Pediatric development |
No current program identified |
| New formulation development |
No current program identified |
| Combination therapy |
No current program identified |
| Biosimilar development |
Not applicable |
Historical publications involving phenindione do not represent an active pipeline. Most are pharmacology studies, historical anticoagulation comparisons or case reports rather than trials designed to support a modern regulatory submission.
The absence of current trials reflects the drug’s clinical disadvantages. A sponsor would need to demonstrate that phenindione provides a material benefit over warfarin, apixaban, rivaroxaban, dabigatran and edoxaban while addressing its known toxicity profile. That evidence threshold is commercially difficult to meet.
What is the FDA regulatory status of phenindione?
Phenindione does not have a meaningful current FDA-approved commercial status in the United States. It is not a standard product in the FDA-approved anticoagulant market and is not an active competitor to warfarin or direct oral anticoagulants.
The FDA’s current anticoagulant framework is dominated by approved products with established manufacturing, labeling and pharmacovigilance systems. Phenindione is not a conventional U.S. prescription-market product and does not have a visible current commercial role in FDA-regulated anticoagulation practice [2].
What is the Orange Book status of phenindione?
Phenindione is not recognized as a current commercially relevant Orange Book reference-listed drug. A current Orange Book entry would normally support an approved reference product, abbreviated new drug applications and potential Paragraph IV litigation. Phenindione has no comparable U.S. generic-launch ecosystem.
| Orange Book issue |
Assessment |
| Current reference-listed drug |
No meaningful current listing identified |
| Active U.S. NDA market |
None of commercial significance |
| ANDA competition |
No established market |
| Paragraph IV activity |
No current litigation pattern identified |
| Hatch-Waxman exclusivity |
None of practical commercial relevance |
The lack of an active reference product materially reduces the likelihood of a conventional generic launch. A company seeking to reintroduce phenindione would likely face a full regulatory and clinical-development exercise rather than a straightforward ANDA strategy.
When did phenindione lose exclusivity?
Phenindione’s original composition-of-matter and use patents are historical and are not expected to create current market exclusivity. The compound was introduced many decades ago, placing any ordinary patent protection far beyond its enforceable term under modern patent-duration rules.
There is no commercially meaningful active patent estate protecting the original phenindione molecule. Any historical patents associated with the compound, early formulations or anticoagulant uses would have expired decades ago or would no longer block market entry.
What patents protect phenindione?
No active, commercially relevant U.S. patent estate has been identified for:
- Phenindione as a chemical entity
- Conventional oral phenindione tablets
- Historical anticoagulation indications
- Standard phenindione manufacturing
- Routine dosage regimens
- Legacy formulations
A newly developed formulation, delivery system or combination product could theoretically generate patentable subject matter. Such patents would protect the new product architecture, not the public-domain phenindione molecule itself. A new formulation would still need to address the drug’s safety liabilities and demonstrate clinical utility.
Are there Paragraph IV challenges or patent litigation involving phenindione?
There is no current Paragraph IV litigation of commercial significance involving phenindione. The absence of litigation is consistent with the lack of an active U.S. reference product, live formulation patents and meaningful generic competition.
| Litigation category |
Current assessment |
| Paragraph IV certification disputes |
None of commercial significance identified |
| ANDA patent litigation |
None identified |
| Hatch-Waxman settlements |
None identified |
| Patent-term-extension disputes |
None identified |
| Formulation-patent disputes |
None identified |
| Method-of-use litigation |
None identified |
A renewed product could create future litigation only if a sponsor obtained patents around a novel formulation, dosing method, pharmacogenomic selection strategy or combination therapy. Those rights would be prospective and product-specific.
What formulations are protected by phenindione patents?
No currently enforceable formulation estate of commercial importance has been identified. Historical phenindione products were conventional oral dosage forms. The principal technical barriers were manufacturing quality, dose uniformity, stability and anticoagulant consistency rather than sophisticated delivery technology.
Potential modern formulation strategies could include:
- Modified-release tablets
- Lower-dose pediatric products
- Liquid oral formulations
- Fixed-dose combinations
- Pharmacogenomically guided dosing
- Abuse-resistant or adherence-oriented packaging
These approaches would face a difficult benefit-risk assessment. A formulation patent cannot remove the underlying systemic risks associated with phenindione exposure.
How strong is the phenindione patent estate?
The current patent estate is effectively weak for commercial purposes.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Core therapeutic-use protection |
Expired or commercially irrelevant |
| Formulation protection |
No active material estate identified |
| Manufacturing protection |
No current blocking estate identified |
| Regulatory exclusivity |
None of practical relevance |
| Freedom to operate for the molecule |
Broad, subject to ordinary process and product review |
| Ability to support premium pricing |
Very limited |
The absence of patent protection would normally favor low-cost generic supply. In phenindione’s case, however, low intellectual-property barriers do not create an attractive market because clinical demand is minimal and regulatory re-entry would be expensive.
Which companies are challenging or developing phenindione?
No major pharmaceutical company has a visible current phenindione development or commercialization program. The competitive set consists of established anticoagulants rather than phenindione manufacturers.
Competitive comparison
| Drug |
Class |
Current clinical role |
Commercial position |
| Phenindione |
Indandione vitamin K antagonist |
Historical or limited legacy use |
Negligible |
| Warfarin |
Coumarin vitamin K antagonist |
Established, especially for mechanical valves |
Mature generic market |
| Apixaban |
Direct factor Xa inhibitor |
Broad use in atrial fibrillation and VTE |
Major branded and post-exclusivity market |
| Rivaroxaban |
Direct factor Xa inhibitor |
Broad use in atrial fibrillation and VTE |
Major branded and generic-transition market |
| Dabigatran |
Direct thrombin inhibitor |
Established but narrower use |
Mature branded/generic-transition market |
| Edoxaban |
Direct factor Xa inhibitor |
Established in selected markets |
Smaller DOAC market |
Warfarin remains the most relevant comparator because both drugs require anticoagulation management through vitamin K pathway inhibition. Direct oral anticoagulants have a stronger commercial position in many indications because they offer fixed dosing and do not require routine INR monitoring. Warfarin remains preferred or necessary in several settings, particularly mechanical heart valves, but this does not materially improve the outlook for phenindione.
What is the market size and revenue exposure for phenindione?
Phenindione has no transparent, investable global market with reliable branded sales data. Its current revenue is expected to be immaterial relative to the global anticoagulant market.
The drug’s addressable market is constrained by:
- Discontinuation or nonavailability in major markets.
- Limited physician familiarity.
- Safer and better-established alternatives.
- Absence of active commercial promotion.
- Significant monitoring and adverse-event burdens.
- Lack of payer or guideline momentum.
- No meaningful patent-based pricing opportunity.
Market projection, 2025-2030
| Year |
Expected commercial position |
Market outlook |
| 2025 |
Legacy or negligible supply |
No meaningful growth |
| 2026 |
No visible clinical-development catalyst |
Flat to declining |
| 2027 |
Continued substitution by warfarin and DOACs |
Negligible |
| 2028 |
No expected regulatory expansion |
Negligible |
| 2029 |
Limited archival or local-market use |
Negligible |
| 2030 |
No credible mainstream re-entry case |
Negligible |
A numerical forecast would imply a level of market visibility that does not exist for phenindione. The defensible projection is that phenindione remains commercially immaterial through 2030 unless a sponsor undertakes a new clinical program and secures regulatory approval.
What generic entry risks exist for phenindione?
Traditional generic-entry risk is low because there is little active branded business to disrupt. Reintroduction risk is different. If a company launches a new phenindione product, the principal threats would include:
- Rapid price competition because the active ingredient is old and unprotected.
- Physician reluctance to switch from warfarin or DOACs.
- Regulatory demands for contemporary safety evidence.
- Product-liability exposure from severe hypersensitivity reactions.
- Procurement exclusion due to limited formulary demand.
- Difficulty establishing a reliable supply chain.
- Lack of reimbursement incentives.
A low-cost generic could enter a market if a regulatory pathway were available, but market access would not guarantee meaningful uptake.
What geographic markets could support phenindione?
No major geographic market appears positioned for broad phenindione adoption. Historical availability has varied by country, and discontinuation decisions have often reflected safety, supply and therapeutic-substitution considerations.
Potential niche demand could arise in jurisdictions where:
- Warfarin supply is unreliable.
- Local formularies retain older anticoagulants.
- Cost pressures favor legacy products.
- Specialized hospitals maintain historical protocols.
These factors would support small, fragmented demand rather than a global branded opportunity. There is no evidence of a geographic expansion strategy by a major manufacturer.
What manufacturing and intellectual-property barriers affect phenindione?
The molecule itself is not protected by current composition-of-matter patents. Manufacturing barriers are therefore operational and regulatory:
- Qualified active-pharmaceutical-ingredient supply
- Validated impurity controls
- Tablet dose uniformity
- Stability data
- Good Manufacturing Practice compliance
- Batch-to-batch potency control
- Pharmacovigilance infrastructure
- Regulatory documentation for an obsolete or discontinued product
The greatest barrier is not synthesis. It is the cost of proving that commercial reintroduction is justified despite available alternatives and known toxicity concerns.
Key Takeaways
- Phenindione has no meaningful active clinical-trial pipeline.
- The drug has no material current FDA or Orange Book position.
- Original molecule and historical-use patents are expired or commercially irrelevant.
- No current Paragraph IV litigation or significant patent dispute has been identified.
- Phenindione was displaced by warfarin and direct oral anticoagulants.
- Current revenue exposure is negligible and lacks reliable public market data.
- The 2025-2030 outlook is flat at a negligible base.
- A new formulation could obtain patents, but the public-domain molecule would remain unprotected.
- Re-entry would require clinical, regulatory and pharmacovigilance investment disproportionate to likely demand.
- The principal commercial risk is not generic erosion. It is lack of clinical and market acceptance.
FAQs
Is phenindione still prescribed?
Phenindione is not a standard anticoagulant in contemporary mainstream practice. Any remaining use is likely limited to legacy or highly localized settings.
Is phenindione safer than warfarin?
Phenindione is not generally regarded as a safer alternative to warfarin. Its historical use declined because of serious hypersensitivity and hematologic complications.
Can a company launch a generic phenindione product?
The molecule is old and no longer protected by ordinary patent exclusivity. A company would still need an appropriate regulatory pathway, qualified manufacturing and evidence supporting current safety and efficacy requirements.
Does phenindione have biosimilar competition?
No. Phenindione is a small-molecule chemical anticoagulant, so biosimilar rules do not apply. Any competitor would be a generic or otherwise regulated small-molecule product.
Could a new phenindione formulation receive patent protection?
Yes. A novel formulation, delivery system or clinically defined dosing method could potentially receive patent protection if it meets patentability requirements. Such protection would not restore exclusivity to the underlying phenindione molecule.
References
- U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- National Institute for Health and Care Excellence. (n.d.). Anticoagulation and atrial fibrillation guidance. https://www.nice.org.uk/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
